PPP5C — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1196210	0.48	3/20
SCHEMBL454894	0.47	3/20
Tautomycin (SCHEMBL83891)	1.00	2/20
Cantharidin (SCHEMBL152261)	1.00	2/20
Cantharidin (SCHEMBL152262)	1.00	2/20
Demethyl-Cantharidin (SCHEMBL177729)	1.00	2/20
SCHEMBL817509	1.00	2/20
SCHEMBL889228	0.78	2/20
SCHEMBL1572846	0.74	2/20
SCHEMBL889227	0.68	2/20
SCHEMBL889288	0.66	2/20
SCHEMBL889291	0.66	2/20
SCHEMBL889296	0.65	2/20
SCHEMBL889307	0.65	2/20
SCHEMBL820205	0.64	2/20
SCHEMBL823120	0.64	2/20
SCHEMBL889221	0.62	2/20
SCHEMBL889287	0.62	2/20
Endothall (SCHEMBL55158)	0.57	2/20
SCHEMBL820202	0.56	2/20

Clinical trials — most relevant to PPP5C by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	PHASE2	COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome	PHASE1/PHASE2	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma	PHASE2	COMPLETED
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes	PHASE2	COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)	PHASE1/PHASE2	COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Palliative Thoracic Radiotherapy Plus BKM120	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
CircularRNA-microRNA-mRNA Regulatory Axis in IVF	nan	NOT_YET_RECRUITING
Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421	nan	COMPLETED
Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer	nan	COMPLETED
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia	nan	UNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
Studying Phosphorus Metabolism	nan	COMPLETED
The Role of TBC1D4 in Exercise- and Insulin-induced Glucose Metabolism in Human Skeletal Muscle	nan	COMPLETED
99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis	nan	COMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a PPP5C binder may also engage these)

Protein	Name	Similarity
P53042	—	0.997	P53042 →
Q60676	—	0.997	Q60676 →
Q2U919	—	0.976	Q2U919 →
Q9NES8	—	0.955	Q9NES8 →
Q9VE51	—	0.949	Q9VE51 →
Q0G819	—	0.949	Q0G819 →
P48455	—	0.948	P48455 →
ACSL1	Long-chain-fatty-acid--CoA ligase 1	0.947	landscape →
Q9VAH9	—	0.946	Q9VAH9 →
Q9VXF1	—	0.945	Q9VXF1 →
P18163	—	0.944	P18163 →
P41216	—	0.944	P41216 →
Q5RDM4	—	0.943	Q5RDM4 →
A0A7U2QYM2	—	0.943	A0A7U2QYM2 →
Q61316	—	0.943	Q61316 →
Q9JID6	—	0.942	Q9JID6 →
Q4WUR1	—	0.941	Q4WUR1 →
O88600	—	0.940	O88600 →
HSPA4	Heat shock 70 kDa protein 4	0.940	landscape →
Q6H8D6	—	0.940	Q6H8D6 →
Q05681	—	0.940	Q05681 →
Q84XU2	—	0.939	Q84XU2 →
A0A0K9RL25	—	0.939	A0A0K9RL25 →
B9N1F9	—	0.939	B9N1F9 →
O13396	—	0.938	O13396 →
Q27889	—	0.938	Q27889 →
Q2TFN9	—	0.938	Q2TFN9 →
Q5R8R4	—	0.937	Q5R8R4 →
P48722	—	0.937	P48722 →
Q6H8D5	—	0.937	Q6H8D5 →